The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Aim
To evaluate HbA1c and body weight changes when semaglutide 0.5‐ or 1.0‐mg once‐weekly (QW) is switched to dulaglutide 3.0‐ or 4.5‐mg QW via exposure‐response modelling.
Methods
HbA1c and body weight time‐course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD‐11 trial for dulaglutide. Simulations were conducted for HbA1c and body weight...